TORONTO, Nov 6 (Reuters) - Biovail Corp reported a lower third-quarter profit on Thursday as generic versions of its key Wellbutrin anti-depressant and restructuring charges bit into results and it warned that the hangover from the restructuring would linger for the next few quarters.
